Publications
526
Citations
53,382
Est. group size
—
Recurring co-author estimate
Active years
44
Publishing since 1983
Ken Mackie studies how cannabinoids (compounds related to cannabis, including cannabidiol/CBD and THC) and the body's own endocannabinoid system affect the brain and nervous system. His research examines cannabinoid receptors and related enzymes in relation to pain, stress, mood, and cognition, and increasingly overlaps with engineered brain organoids and devices that interface with neural tissue. The work sits at the intersection of pharmacology, neuroscience, and biomedical engineering.
Publication output has been steady at roughly 20 papers per year for most of the decade, with a somewhat lower count in the two most recent years.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Author Correction: Acoustic metamaterials-driven transdermal drug delivery for rapid and on-demand management of acute disease
Nature Communications · 2026
- Biocomputing-with-Brainoware: Version 1.0.0
Zenodo (CERN European Organization for Nuclear Research) · 2026
- Interfacing biological neural networks with three-dimensional devices
Nature Electronics · 2026
- Cannabidiol reduces the latency for the behavioral effect of escitalopram in chronically stressed male mice: involvement of NAPE-PLD expressed in parvalbumin-positive interneurons and the prefrontal cortex
Neuropharmacology · 2026
- Cellular Mobilization of 2-AG In Vitro Measured Using an eCB GRAB Approach (Abstract ID: 227198)
Journal of Pharmacology and Experimental Therapeutics · 2026
- Cannabidiol attenuates chemotherapy-induced peripheral neuropathic pain through a mechanism that requires the enzyme N-acylphosphatidylehtanolamine-specific phospoholipase D (NAPE-PLD)
Zenodo (CERN European Organization for Nuclear Research) · 2026
- Cannabidiol attenuates chemotherapy-induced peripheral neuropathic pain through a mechanism that requires the enzyme N-acylphosphatidylehtanolamine-specific phospoholipase D (NAPE-PLD)
Zenodo (CERN European Organization for Nuclear Research) · 2026
- Organoid Brain‐Machine‐Interface Devices for Central Nervous System Repair
Advanced Science · 2026
- Biocomputing-with-Brainoware: Version 1.0.0
Open MIND · 2026
- Muscarinic cannabinoid suppression of excitation, a novel form of coincidence detection
Pharmacological Research · 2025
- CB1 and CB2 receptors differentially modulate the cognitive impact of maternal immune activation and perinatal cannabinoid exposure
Behavioural Brain Research · 2025
- Intelligent sensing devices and systems for personalized mental health
Med-X · 2025
- A 2D cell segmentation protocol for monitoring multiple STAT signaling pathways by fluorescence microscopy
STAR Protocols · 2025
- Vascular network-inspired diffusible scaffolds for engineering functional midbrain organoids
Cell stem cell · 2025
- Chiral Me-2-arachidonoyl Glycerols: The First Potent Endocannabinoid Glyceride Templates with Stability to COX-2
ACS Medicinal Chemistry Letters · 2024
- bioRxiv (Cold Spring Harbor Laboratory)×25
- Cannabis and Cannabinoid Research×9
- Neuropharmacology×9
- Pharmacological Research×8
- Nature Communications×5
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile